Status:
COMPLETED
Vitamin-D Receptor Activation (VDRA) in Chronic Kidney Disease
Lead Sponsor:
Danderyd Hospital
Collaborating Sponsors:
Abbott
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
20+ years
Phase:
PHASE2
PHASE3
Brief Summary
To investigate whether treatment with a vitamin-D receptor activator is able to improve important markers of cardiovascular risk.
Detailed Description
Main question: May 12 weeks of VDRA treatment reduce the pathological sympathetic overactivation associated with moderate kidney disease? Secondary questions aim to thrown light on how VDRAs can red...
Eligibility Criteria
Inclusion
- eGFR 15-59 ml/m2
Exclusion
- Current vitamin D treatment
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT01204528
Start Date
September 1 2010
End Date
July 1 2013
Last Update
September 5 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karolinska Institute at Danderyd University Hospital
Danderyd, Stockholm County, Sweden, 18288